Table 2.
Questionnaire Scale | Level | MIGS (n=93) |
KDB (n=50) |
iStent (n=13) |
GATT (n=7) |
iStent Inject (n=23) |
P-value* |
---|---|---|---|---|---|---|---|
Vision | |||||||
Better | 83.9% (78) | 78.0% (39) | 76.9% (10) | 85.7% (6) | 100% (23) | 0.277 | |
No Change | 8.6% (8) | 12.0% (6) | 15.4% (2) | 0% (0) | 0% (0) | ||
Worse | 7.5% (7) | 10.0% (5) | 7.7% (1) | 14.3% (1) | 0% (0) | ||
Redness | |||||||
Better | 40.9% (38) | 42.0% (21) | 30.8% (4) | 0% (0) | 56.5% (13) | 0.033 | |
No change | 11.8% (11) | 14.0% (7) | 0% (0) | 0% (0) | 17.4% (4) | ||
Worse | 3.2% (3) | 4.0% (2) | 0% (0) | 14.3% (1) | 0% (0) | ||
No redness before | 44.1% (41) | 40.0% (20) | 69.2% (9) | 85.7% (6) | 26.1% (6) | ||
Itching | |||||||
Better | 25.8% (24) | 20.0% (10) | 30.8% (4) | 0% (0) | 43.5% (10) | 0.189 | |
No change | 16.1% (15) | 20.0% (10) | 7.7% (1) | 0% (0) | 17.4% (4) | ||
Worse | 10.8% (10) | 10.0% (5) | 7.7% (1) | 14.3% (1) | 13.0% (3) | ||
No itching before | 47.3% (44) | 50.0% (25) | 53.8% (7) | 85.7% (6) | 26.1% (6) | ||
Pain | |||||||
Better | 35.5% (33) | 36.0% (18) | 53.8% (7) | 14.3% (1) | 30.4% (7) | 0.052 | |
No change | 9.7% (9) | 4.0% (2) | 7.7% (1) | 0% (0) | 26.1% (6) | ||
Worse | 8.6% (8) | 10.0% (5) | 0% (0) | 28.6% (2) | 4.3% (1) | ||
No pain before | 46.2% (43) | 50.0% (25) | 38.5% (5) | 57.1% (4) | 39.1% (9) | ||
Occupational life | |||||||
Better | 14.8% (13) | 16.3% (8) | 7.7% (1) | 0% (0) | 21.1% (4) | 0.490 | |
No change | 85.2% (75) | 83.7% (41) | 92.3% (12) | 100% (7) | 78.9% (15) | ||
Worse | 0% (0) | 0% (0) | 0% (0) | 0% (0) | 0% (0) | ||
Social life | |||||||
Better | 36.6% (30) | 35.6% (16) | 38.5% (5) | 0% (0) | 52.9% (9) | 0.209 | |
No change | 59.8% (49) | 60.0% (27) | 61.5% (8) | 85.7% (6) | 47.1% (8) | ||
Worse | 3.7% (3) | 4.4% (2) | 0% (0) | 14.3% (1) | 0% (0) | ||
Economic status | |||||||
Better | 1.1% (1) | 2.0% (1) | 0% (0) | 0% (0) | 0% (0) | 0.853 | |
No change | 98.9% (86) | 98.0% (48) | 100% (13) | 100% (7) | 100% (18) | ||
Worse | 0% (0) | 0% (0) | 0% (0) | 0% (0) | 0% (0) | ||
Sleep | |||||||
Better | 27.1% (23) | 26.5% (13) | 30.8% (4) | 0% (0) | 33.3% (6) | 0.489 | |
No change | 68.2% (58) | 65.3% (32) | 69.2% (9) | 100% (5) | 66.7% (12) | ||
Worse | 4.7% (4) | 8.2% (4) | 0% (0) | 0% (0) | 0% (0) | ||
Hospital followup | |||||||
Decreased | 55.9% (52) | 60.0% (30) | 61.5% (8) | 85.7% (6) | 34.8% (8) | 0.255 | |
No change | 40.9% (38) | 36.0% (18) | 38.5% (5) | 14.3% (1) | 60.9% (14) | ||
Increased | 3.2% (3) | 4.0% (2) | 0% (0) | 0% (0) | 4.3% (1) | ||
ER visits | |||||||
Decreased | 31.2% (29) | 36.0% (18) | 23.1% (3) | 57.1% (4) | 17.4% (4) | 0.399 | |
No change | 67.7% (63) | 62.0% (31) | 76.9% (10) | 42.9% (3) | 82.6% (19) | ||
Increased | 1.1% (1) | 2.0% (1) | 0% (0) | 0% (0) | 0% (0) | ||
Dependency | |||||||
Decreased | 12.9% (12) | 24.0% (12) | 0% (0) | 0% (0) | 0% (0) | 0.029 | |
No change | 78.5% (73) | 66.0% (33) | 100% (13) | 85.7% (6) | 91.3% (21) | ||
Increased | 8.6% (8) | 10.0% (5) | 0% (0) | 14.3% (1) | 8.7% (2) | ||
Satisfaction | |||||||
Satisfied | 86.0% (80) | 80.0% (40) | 84.6% (11) | 85.7% (6) | 100% (23) | 0.232 | |
No difference | 5.4% (5) | 10.0% (5) | 0% (0) | 0% (0) | 0% (0) | ||
Unsatisfied | 8.6% (8) | 10.0% (5) | 15.4% (2) | 14.3% (1) | 0% (0) | ||
Overall QOL | |||||||
Improved | 79.6% (74) | 74.0% (37) | 69.2% | 85.7% (6) | 95.7% (22) | 0.109 | |
Same as before | 14.0% (13) | 16.0% (8) | 30.8% (4) | 0% (0) | 4.3% (1) | ||
Worse | 6.5% (6) | 10.0% (5) | 0% (0) | 14.3% (1) | 0% (0) |
Note: *Chi-square test was performed.
Abbreviations: MIGS, minimally invasive glaucoma surgery; KDB, Kahook Dual Blade; GATT, gonioscopy-assisted transluminal trabeculotomy; POAG, primary open-angle glaucoma; SOAG, secondary open-angle glaucoma; PACG, primary angle-closure glaucoma; NTG, normal-tension glaucoma; PXF, pseudoexfoliation glaucoma.